AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Gaxos.ai Inc.

$0.64 -$0.52 (-45.09%)
NASDAQ · 15 Sep 2026 17:49 UTC
Previous Close
$0.65
Day Range
$0.61$0.65
Year Range
$0.61$2.63
Market Cap
6.51M
AVG Volume
3.07M
Trailing/Forward PE
-1.28/-
PEG ratio
-0.38
Dividend Yield
-
Next Earnings Date
2026-11-12
Primary Exchange
NASDAQUS
Revenue (USD)
0500K1M1.5M2M2022202320242025
GXAI Revenue (USD) by year
PeriodRevenue (USD)
20251.93M
20244.03K
2023256
20220
Net Income (USD)
-4M-3M-2M-1M02022202320242025
GXAI Net Income (USD) by year
PeriodNet Income (USD)
2025-3.9M
2024-3.42M
2023-3.95M
2022-1.42M
Operating Income (USD)
-6M-4M-2M02022202320242025
GXAI Operating Income (USD) by year
PeriodOperating Income (USD)
2025-4.92M
2024-3.7M
2023-3.96M
2022-1.42M
EBITDA (USD)
-6M-4M-2M02022202320242025
GXAI EBITDA (USD) by year
PeriodEBITDA (USD)
2025-4.71M
2024-3.37M
2023-3.94M
2022-1.42M
Cash Flows (USD)
-6M-4M-2M02022202320242025
GXAI Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-4.44M
2024-3.33M
2023-3.04M
2022-1.26M
EPS (USD)
-6-4-202022202320242025
GXAI EPS (USD) by year
PeriodEPS (USD)
2025-0.55
2024-2.36
2023-4.04
2022-1.63
Expenses (USD)
02M4M6M8MR&DSG&ACapex2022202320242025
GXAI Expenses (USD) by year
PeriodExpenses (USD)
20257.43M
20243.73M
20234.01M
20221.42M
Cash & Debt (USD)
05M10M15M20M2022202320242025
GXAI Cash & Debt (USD) by year
PeriodCash & Debt (USD)
202512.37M
202416.77M
20233.62M
2022679.78K
Debt ratios
00.511.522025
GXAI Debt ratios by year
PeriodDebt ratios
20250.92
Margins
-6000%-4000%-2000%0%2000%202320242025
GXAI Margins by year
PeriodMargins
202593.97%
2024-467.32%
2023-4059.77%
Return on Capital
-300%-200%-100%0%2022202320242025
GXAI Return on Capital by year
PeriodReturn on Capital
2025-30.61%
2024-20.56%
2023-115.24%
2022-207.25%
Shares Outstanding
02M4M6M8M2022202320242025
GXAI Shares Outstanding by year
PeriodShares Outstanding
20257.09M
20246.92M
2023997.88K
2022868.16K
Book Value Per Share (USD)
012342022202320242025
GXAI Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20251.8
20242.4
20233.43
20220.79
Total Assets (USD)
05M10M15M20M2022202320242025
GXAI Total Assets (USD) by year
PeriodTotal Assets (USD)
202513.42M
202417.02M
20233.7M
2022941.43K
Employee Count
0123420242025
GXAI Employee Count by year
PeriodEmployee Count
20253
20243
Free Cash Flow Yield
-300%-200%-100%0%med -50.21%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
GXAI Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-81.07%
Sep 26-77.34%
Sep 26-69.67%
Aug 26-67.49%
Aug 26-59.86%
Aug 26-63.38%
Aug 26-69.51%
Jul 26-78.78%
Jul 26-55.74%
Jul 26-54.71%
Jul 26-52.75%
Jul 26-50.93%
Jun 26-50.5%
Jun 26-48.43%
Jun 26-49.24%
Jun 26-42.81%
May 26-50.07%
May 26-50.07%
May 26-49.24%
May 26-49.64%
May 26-48.87%
Apr 26-46.33%
Apr 26-50.04%
Apr 26-51.69%
Apr 26-48.49%
Mar 26-52.12%
Mar 26-47.39%
Mar 26-45.55%
Mar 26-38.8%
Feb 26-55.13%
Feb 26-48.72%
Feb 26-59.86%
Feb 26-43.35%
Jan 26-41.9%
Jan 26-56.12%
Jan 26-55.62%
Jan 26-52.38%
Jan 26-54.18%
Dec 25-59.3%
Dec 25-59.3%
Dec 25-55.62%
Dec 25-51.1%
Nov 25-47.98%
Nov 25-54.18%
Nov 25-48.35%
Nov 25-39.98%
Oct 25-34.2%
Oct 25-31.07%
Oct 25-32.37%
Oct 25-29.88%
Oct 25-31.99%
Sep 25-32.18%
Sep 25-31.8%
Sep 25-31.62%
Sep 25-34.86%
Aug 25-31.62%
Aug 25-26.14%
Aug 25-50.35%
Aug 25-52.22%
Aug 25-48.55%
Jul 25-44.28%
Jul 25-44.64%
Jul 25-44.64%
Jul 25-35.25%
Jun 25-38.98%
Jun 25-40.11%
Jun 25-44.64%
Jun 25-39.26%
May 25-38.71%
May 25-38.98%
May 25-41.93%
May 25-40.36%
May 25-41.41%
Apr 25-41.41%
Apr 25-43.67%
Apr 25-42.89%
Apr 25-41.05%
Mar 25-41.41%
Mar 25-190.38%
Mar 25-187.26%
Mar 25-181.32%
Feb 25-196.95%
Feb 25-162.03%
Feb 25-127.63%
Feb 25-150.3%
Jan 25-150.3%
Jan 25-114.8%
Jan 25-114.23%
Jan 25-104.8%
Jan 25-78.24%
Dec 24-76.92%
Dec 24-95.59%
Dec 24-65.46%
Dec 24-87.87%
Nov 24-178.48%
Nov 24-191.98%
Nov 24-162.03%
Nov 24-224.18%
Nov 24-233.92%
Oct 24-232.24%
Price to Sales
0200040006000med 60.4Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
GXAI Price to Sales by year
PeriodPrice to Sales
Sep 261.12
Sep 261.18
Sep 261.3
Aug 261.35
Aug 261.52
Aug 261.43
Aug 261.98
Jul 261.74
Jul 262.47
Jul 262.51
Jul 262.6
Jul 262.7
Jun 262.72
Jun 262.84
Jun 262.79
Jun 263.21
May 262.74
May 262.74
May 262.79
May 264.62
May 264.7
Apr 264.95
Apr 264.59
Apr 264.44
Apr 264.73
Mar 264.4
Mar 264.84
Mar 2614.16
Mar 2616.62
Feb 2611.7
Feb 2613.24
Feb 2610.77
Feb 2614.88
Jan 2615.39
Jan 2611.49
Jan 2611.59
Jan 2612.31
Jan 2611.9
Dec 2510.88
Dec 2510.88
Dec 2511.59
Dec 2512.62
Nov 2513.44
Nov 2511.9
Nov 2513.34
Nov 2548.75
Oct 2557
Oct 2562.73
Oct 2560.23
Oct 2565.24
Oct 2560.94
Sep 2560.58
Sep 2561.3
Sep 2561.66
Sep 2555.92
Aug 2561.66
Aug 2574.56
Aug 2538.72
Aug 25267.53
Aug 25287.72
Jul 25315.48
Jul 25312.96
Jul 25312.96
Jul 25396.25
Jun 25358.39
Jun 25348.29
Jun 25312.96
Jun 25355.87
May 25360.91
May 25358.39
May 25333.15
May 252045.92
May 251994.34
Apr 251994.34
Apr 251891.18
Apr 251925.57
Apr 252011.53
Mar 251994.34
Mar 25571.4
Mar 25580.93
Mar 25599.97
Feb 25552.36
Feb 25671.4
Feb 25852.34
Feb 25723.78
Jan 25723.78
Jan 25947.58
Jan 25952.34
Jan 251038.05
Jan 251390.41
Dec 241414.22
Dec 241138.04
Dec 241661.83
Dec 241238.04
Nov 24609.5
Nov 24566.64
Nov 24671.4
Nov 245863.67
Nov 245619.35
Oct 245660.07
Price to Book
0.20.40.60.81med 0.6Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
GXAI Price to Book by year
PeriodPrice to Book
Sep 260.41
Sep 260.43
Sep 260.48
Aug 260.5
Aug 260.56
Aug 260.53
Aug 260.48
Jul 260.43
Jul 260.6
Jul 260.61
Jul 260.64
Jul 260.66
Jun 260.66
Jun 260.69
Jun 260.68
Jun 260.78
May 260.67
May 260.67
May 260.68
May 260.7
May 260.71
Apr 260.75
Apr 260.7
Apr 260.67
Apr 260.72
Mar 260.67
Mar 260.73
Mar 260.71
Mar 260.83
Feb 260.59
Feb 260.66
Feb 260.54
Feb 260.75
Jan 260.77
Jan 260.58
Jan 260.58
Jan 260.62
Jan 260.6
Dec 250.55
Dec 250.55
Dec 250.58
Dec 250.63
Nov 250.67
Nov 250.6
Nov 250.67
Nov 250.65
Oct 250.76
Oct 250.84
Oct 250.8
Oct 250.87
Oct 250.81
Sep 250.81
Sep 250.82
Sep 250.82
Sep 250.75
Aug 250.82
Aug 250.99
Aug 250.52
Aug 250.48
Aug 250.51
Jul 250.56
Jul 250.56
Jul 250.56
Jul 250.7
Jun 250.64
Jun 250.62
Jun 250.56
Jun 250.63
May 250.64
May 250.64
May 250.59
May 250.5
May 250.48
Apr 250.48
Apr 250.46
Apr 250.47
Apr 250.49
Mar 250.48
Mar 250.25
Mar 250.26
Mar 250.27
Feb 250.25
Feb 250.3
Feb 250.38
Feb 250.32
Jan 250.32
Jan 250.42
Jan 250.42
Jan 250.46
Jan 250.62
Dec 240.63
Dec 240.5
Dec 240.74
Dec 240.55
Nov 240.27
Nov 240.25
Nov 240.3
Nov 240.34
Nov 240.33
Oct 240.33
Gaxos.ai Inc.
GXAI
Stockpicker

Video analysis: GXAI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: GXAI

Gaxos.ai Inc. Raises $3.6 Million in Gross Proceeds from Warrant Exercise Transaction

globenewswire.com · 17 Aug 2026

Gaxos.ai Inc. Raises $3.6 Million in Gross Proceeds from Warrant Exercise Transaction

Roseland, NJ, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. (NASDAQ: GXAI), (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various high-growth sectors, today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 3,007,654 shares of common stock originally issued in December 2024 and September 2024, having exercise prices ranging from $2.33 to $3.32 per share, at a reduced exercise price of $1.20 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statements on Form S-1 (No. 333-292709) and Form S-3 (File No. 333-282739).

Gaxos Announces Exercise of Warrants for Approximately $3.6 Million Gross Proceeds

globenewswire.com · 14 Aug 2026

Gaxos Announces Exercise of Warrants for Approximately $3.6 Million Gross Proceeds

Roseland, NJ, Aug. 14, 2026 (GLOBE NEWSWIRE) -- --Gaxos.ai Inc. (“Gaxos” or the “Company”)(NASDAQ: GXAI), a company developing artificial intelligence applications across various high-growth sectors, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 3,007,654 shares originally issued in December 2024 and September 2024, having exercise prices ranging from $2.33 to $3.32 per share, at a reduced exercise price of $1.20 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statements on Form S-1 (No. 333-292709) and Form S-3 (File No. 333-282739).

Gaxos Delivers Record Second-Quarter Revenue, Up 35.8% Sequentially and 1,337% Year over Year

globenewswire.com · 12 Aug 2026

Gaxos Delivers Record Second-Quarter Revenue, Up 35.8% Sequentially and 1,337% Year over Year

Revenue growth significantly outpaces advertising expense growth as revenue generated per advertising dollar improves Roseland, NJ, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company")(NASDAQ: GXAI), a company developing artificial intelligence applications across various high-growth sectors, today reported financial and operating results for the three and six months ended June 30, 2026. Second-quarter consolidated revenue reached a record of $2.46 million, representing an increase of 35.8% from $1.81 million in the first quarter of 2026 and an increase of 1,337% from $0.17 million in second quarter of 2025.

Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL)

defenseworld.net · 4 Aug 2026

Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL)

Castle Biosciences (NASDAQ: CSTL - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Castle Biosciences

Gaxos Announces $1,000,000 Share Repurchase Plan

globenewswire.com · 3 Aug 2026

Gaxos Announces $1,000,000 Share Repurchase Plan

Roseland, NJ , Aug. 03, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company")(NASDAQ: GXAI), a company developing artificial intelligence applications across various high-growth sectors, today announced that its Board of Directors has authorized a new share repurchase program, under which the Company may repurchase, from time to time, up to an aggregate of $1,000,000 of the Company's common stock.

Gaxos Sharpens Focus to Accelerate Growth Across Revenue-Generating AI and Health and Wellness Platforms

globenewswire.com · 28 Jul 2026

Gaxos Sharpens Focus to Accelerate Growth Across Revenue-Generating AI and Health and Wellness Platforms

Gaming divestiture strengthens operating strategy around commercial traction and customer acquisition efficiency. Q1 revenue increases to $1.81 million.

Gaxos.ai Inc. Sells Gaming Assets to Game Foundry AI

globenewswire.com · 24 Jun 2026

Gaxos.ai Inc. Sells Gaming Assets to Game Foundry AI

Transaction streamlines operations and positions Gaxos to focus on revenue-generating, higher-margin opportunities Roseland, NJ, June 24, 2026 (GLOBE NEWSWIRE) -- Gaxos.ai Inc. ("Gaxos" or the "Company"), a company developing artificial intelligence applications across various high-growth sectors, today announced that it had completed the sale of its gaming assets, including its portfolio of mobile games and Gaxos Gaming Labs, a generative AI service that empowers game developers and publishers, to Game Foundry AI, a privately-held company. The transaction was structured as an all-stock deal valued at approximately $1.76 million.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.